{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:41:23Z","timestamp":1792014083802,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40256-024-00672-2","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T12:28:00Z","timestamp":1724329680000},"page":"791-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Real\u2011World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten"],"prefix":"10.1007","volume":"24","author":[{"given":"Zeynep","family":"Yukselen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind Kumar Venkataramana","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramukh Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Ujjawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahati","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyash","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nakhla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannu","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3434-6136","authenticated-orcid":false,"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"39","key":"672_CR1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"C Muneretto","year":"2014","unstructured":"Muneretto C, Elliott P, Anastasakis A, Borger M, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733\u201379.","journal-title":"Eur Heart J"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1093\/eurheartj\/ehad429","volume":"44","author":"JH DeVries","year":"2023","unstructured":"DeVries JH, Irs A, Hillege HL. The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. Eur Heart Fail. 2023;44(37):3492\u20134.","journal-title":"Eur Heart Fail"},{"issue":"10253","key":"672_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020;396(10253):759\u201369.","journal-title":"The Lancet"},{"issue":"2","key":"672_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95\u2013108.","journal-title":"J Am Coll Cardiol"},{"issue":"44","key":"672_CR5","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","volume":"44","author":"E Braunwald","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023;44(44):4622\u201333.","journal-title":"Eur Heart J"},{"issue":"1","key":"672_CR6","first-page":"164","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. Heart Fail. 2024;12(1):164\u201377.","journal-title":"Heart Fail"},{"key":"672_CR7","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"issue":"2","key":"672_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"672_CR9","unstructured":"B\u00f6hm R. Primer on disproportionality analysis. Openvigil. 2018. Available at https:\/\/openvigil.sourceforge.net\/doc\/DPA.pdf"},{"key":"672_CR10","first-page":"421","volume":"9","author":"D Madigan","year":"2010","unstructured":"Madigan D, Ryan P, Simpson S, Zorych I. Bayesian methods in pharmacovigilance. Bayesian. Statistics. 2010;9:421\u201338.","journal-title":"Statistics"},{"key":"672_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"28","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;28:789\u2013802.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"672_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"672_CR13","first-page":"491","volume":"25","author":"HL Liao","year":"2024","unstructured":"Liao HL, Liang Y, Liang B. Evaluation of mavacamten in patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2024;25(7):491\u20138.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"672_CR14","unstructured":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. CAMZYOSTM (mavacamten): US prescribing information. 2022. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998s000lbl.pdf."},{"issue":"25","key":"672_CR15","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-240.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"672_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, et al. Effect of mavacamten on chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. 2023;8(10):957\u201365.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"672_CR17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cpt.2172","volume":"109","author":"A Lavertu","year":"2021","unstructured":"Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: Toward real-world data and digital monitoring. Clin Pharmacol Ther. 2021;109(5):1197\u2013202.","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00672-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00672-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00672-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:30:06Z","timestamp":1730305806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00672-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00672-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"31 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zeynep Yukselen: project administration, data curation, formal analysis, software, validation, conceptualization, methodology, writing\u2014original draft, and writing\u2014review & editing. Arvind Kumar Venkataramana Raju: data curation, formal analysis, validation, software, and conceptualization. Pramukh Arun Kumar: writing\u2014original draft and writing\u2014review & editing. Aditi Ujjawal: writing\u2014original draft and writing\u2014review & editing. Mahati Dasari: visualization and writing\u2014review & editing. Shreyash Parajuli: writing\u2014original draft and writing\u2014review & editing. Michael Nakhla: writing\u2014review & editing. Kannu Bansal: data curation, conceptualization, methodology, software, resources, writing\u2014review & editing, and supervision. Sarju Ganatra: writing\u2014review & editing and supervision. Sourbha S. Dani: conceptualization, resources, project administration, software, writing\u2014review & editing, and supervision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Zeynep Yukselen, Arvind Kumar Venkataramana Raju, Pramukh Arun Kumar, Aditi Ujjawal, Mahati Dasari, Shreyash Parajuli, Michael Nakhla, Kannu Bansal, Sarju Ganatra, and Sourbha S. Dani declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability:"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}